Eli Lilly awarded exclusive use of new anti-cancer technology

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated.

Indianapolis-based Eli Lilly has been granted exclusive licensing rights to a new anti-cancer technology.

The deal between the drug-maker and ImmunoGen, Inc., could be worth up to $200 million.

The method uses antibodies to deliver cancer-killing agents to cancer cells. It spares nearby, healthy cells from destruction.

The deal was made possible by a 2011 agreement.